BCL2L1 and posterior cortical atrophy: The “two-way coverage” strategy adopted by the treatment team is innovative: 1) docetaxel can target the microtubule system of PCa (12) and plays an antitumor role by inhibiting the Bcl-xL protein in lung cancer cells (13); 2) the application of karelizumab was based on the newly discovered aberrant expression of programmed death-ligand 1 (PD-L1) in peri-nervous infiltration (14); and 3) dynamic monitoring of PSA and carcinoembryonic antigen (CEA) dual indexes provides a multidimensional basis for efficacy assessment.